title: Unfavorable cancers of unknown primaries: presentation and prognostic factors. A population-based 8-year experience.
abstract: Cancer of unknown primary is a mostly disseminated malignancy where detailed investigations cannot reveal a probable origin. A few subsets may respond to specific therapy, but the large majority of cases have a median survival of 3-4 months in the few population-based reports, which, however, did not use current investigations and therapy. It is not known if survival can be prolonged by chemotherapy or if supportive care is preferable, especially in the most unfavorable cases in whom chemotherapy may impair the quality of life without prolonging it. We therefore studied prognosis of 134 recent population-based consecutive unfavorable patients. Multiple involvements of the liver, nodes, lungs and skeleton, polysymptomatology, and biochemical abnormalities were common. The median survival time was 103 days, and the 1-year survival was 19%. Hypoalbuminemia, weight loss, and anemia in this order were the strongest negative prognostic factors in multivariate analysis, but univariate analysis added involvement of multiple sites or of the liver, high age, male gender, adenocarcinoma histology, and tobacco use as unfavorable factors. About 10% of patients became long-term survivors, sometimes in the presence of one or more of negative prognostic factors but in particular those with limited nodal spread. A previously unreported finding was that nodal involvement of squamous cell carcinoma limited to the iliacoinguinal region could seemingly be cured by surgery ± radiotherapy. In the absence of efficient treatment and controlled therapeutic trials, supportive care alone seems justified for patients with the worst prognostic factors.
authors.affiliation: Department of Oncology and Pathology, Karolinska Institutet, 118 83, Stockholm, Sweden, margareta.randen@ki.se.
authors.forename: Margareta
authors.initials: M
authors.lastname: Randén
authors.forename: Maria
authors.initials: M
authors.lastname: Helde-Frankling
authors.forename: Sara
authors.initials: S
authors.lastname: Runesdotter
authors.forename: Peter
authors.initials: P
authors.lastname: Gunvén
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000401:mortality* / Q000473:pathology*; D011379:Prognosis
references.citation: J Clin Oncol. 1995 Jul;13(7):1720-5
references.pmid: 7541451
references.citation: Eur J Cancer. 2002 Sep;38(13):1810-2
references.pmid: 12175699
references.citation: Clin Radiol. 2002 Dec;57(12):1073-7
references.pmid: 12475531
references.citation: J Clin Oncol. 1994 Jun;12(6):1272-80
references.pmid: 8201389
references.citation: Int J Clin Pract. 2005 Sep;59(9):1051-4
references.pmid: 16115181
references.citation: Acta Oncol. 2009;48(6):915-20
references.pmid: 19363713
references.citation: Cancer. 2006 Jun 1;106(11):2428-36
references.pmid: 16634096
references.citation: Oncology. 2010;78(2):87-93
references.pmid: 20357516
references.citation: Clin Oncol (R Coll Radiol). 2008 Sep;20(7):564
references.pmid: 18501570
references.citation: Semin Oncol. 2009 Feb;36(1):60-4
references.pmid: 19179189
references.citation: J Natl Compr Canc Netw. 2008 Nov;6(10):1061-7
references.pmid: 19176201
references.citation: CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26
references.pmid: 12568441
references.citation: Eur J Gastroenterol Hepatol. 2008 Feb;20(2):104-10
references.pmid: 18188029
references.citation: J Clin Oncol. 2002 Dec 15;20(24):4679-83
references.pmid: 12488413
references.citation: Eur J Cancer. 2002 Feb;38(3):409-13
references.pmid: 11818207
references.citation: Cancer J. 2001 May-Jun;7(3):203-12
references.pmid: 11419028
references.citation: Crit Rev Oncol Hematol. 2009 Mar;69(3):271-8
references.pmid: 18977667
references.citation: Ann Oncol. 2009 May;20 Suppl 4:154-5
references.pmid: 19454441
references.citation: Clin Oncol (R Coll Radiol). 2009 Feb;21(1):43-8
references.pmid: 18976894
references.citation: Cancer. 2013 Feb 15;119(4):756-65
references.pmid: 23319010
references.citation: Cancer. 2006 Dec 1;107(11):2698-705
references.pmid: 17063500
references.citation: Med Pediatr Oncol. 1989;17(3):188-92
references.pmid: 2747591
references.citation: Ann Oncol. 2012 Jul;23(7):1854-63
references.pmid: 22115926
references.citation: Crit Rev Oncol Hematol. 2005 Jun;54(3):243-50
references.pmid: 15890271
references.citation: Acta Oncol. 2007;46(5):592-601
references.pmid: 17562435
references.citation: Clin Cancer Res. 1999 Nov;5(11):3403-10
references.pmid: 10589751
references.citation: Ann Oncol. 2010 Oct;21 Suppl 7:vii303-7
references.pmid: 20943633
references.citation: J Clin Oncol. 1998 Jun;16(6):2105-12
references.pmid: 9626210